Download Free Medical Colorectal Cancer and Gastrointestinal Stromal Tumor: Disease State Overview and New Treatment Approaches PowerPoint Presentation

Colorectal Cancer and Gastrointestinal Stromal Tumor: Disease State Overview and New Treatment Approaches PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Familial Adenomatous Polyposis, which is titled "Colorectal Cancer and Gastrointestinal Stromal Tumor: Disease State Overview and New Treatment Approaches", to know about colorectal cancer (CRC) epidemiology.

Tags : Familial Adenomatous Polyposis, Colorectal Cancer, Gastrointestinal Stromal Tumor

Published on : May 18, 2021 | Views : 1024 | Downloads : 4

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Colorectal Cancer and Gastrointestinal Stromal Tumor: Disease State Overview and New Treatment Approaches Robin M Ross, PharmD Medical Science Liasion
Slide 2-

Colorectal Cancer (CRC) Epidemiology CRC is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the US1 143,460 new cases of CRC are estimated for 20122 ~72% of cases arise in the colon and ~28% arise in the rectum3 CRC incidence rate is more than 15x higher in adults aged ≥50 than in adults aged 20-493 ~20% of patients have metastatic CRC (mCRC) when first diagnosed4 2 NCCN Colon Cancer: Version 1, 2013. American Cancer Society. http://www.cancer.org/acs/groups/cid/documents/webcontent/003096-pdf.pdf. Accessed August 31, 2012. American Cancer Society. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-028323.pdf. Accessed August 31, 2012. National Cancer Institute. http://www.seer.cancer.gov/statfacts/html/colorect.html. Accessed August 31, 2012.
Slide 3-

Not all cases of CRC present with symptoms1 However, a variety of clinical symptoms can be associated with CRC1,2 Signs and Symptoms of CRC 3 Abeloff. 2008. DeVita. 2011.
Slide 4-

Screening for CRC 4 NCCN Colorectal Cancer Screening: Version 1, 2013. Levin B, et al. CA Cancer J Clin. 2008;58:130-160. US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/uspstf08/colocancer/colcancs.pdf. Accessed August 31, 2012. Goals of screening are to detect cancer at an early, curable stage, and to detect and remove adenomatous polyps1 National Comprehensive Cancer Network (NCCN) guidelines recommend screening based on one’s risk status1 The following are applicable to asymptomatic adults ≥50 of age2 Although the US Preventive Services Task Force (USPSTF) recommends screening for people aged 50-75, it does not recommend screening for adults >753
Slide 5-

An accurate diagnosis depends on the implementation of a range of clinical evaluations:1,2 Complete personal and family history Physical examination Laboratory tests (including blood, liver, and kidney tests) Colonoscopy Computed tomography scan (for the detection of possible metastases) Diagnosing CRC 5 Abeloff. 2008. DeVita. 2011.
Slide 6-

Staging CRC (1) Following a CRC diagnosis, a pathological review of an endoscopically removed biopsy sample can determine the stage of CRC, which measures the anatomic extent of disease1,2 The American Joint Committee on Cancer/Tumor Node Metastasis (AJCC/TNM) system is the most prominent and highly regarded:3 6 NCCN Colon Cancer: Version 1, 2013. Abeloff. 2008. DeVita. 2011.
Slide 7-

Staging CRC (2) 7 DeVita. 2011.
Slide 8-

CRC Stage and Five-Year Survival 8 Abeloff. 2008.
Slide 9-

Men Women Prognoses for Patients with mCRC Remain Poor 5-year relative survival rate for patients with CRC was 67% for 1999-2006 Localized: 90% Regional: 70% Distant: 12% 5-year CRC-specific survival by stage and race/ethnicity, 1999-2006: 9 American Cancer Society. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-028323.pdf. Accessed August 31, 2012.
Slide 10-

CRC Risk Factors 10 American Cancer Society. http://www.cancer.org/acs/groups/cid/documents/webcontent/003096-pdf.pdf. Accessed August 31, 2012.
Slide 11-

Biomarkers in CRC: Improving Outcomes Biomarkers in CRC allow: Identification of patients who will benefit most from a specific treatment Improved outcomes Sparing of needless treatment-related toxicity Reduced costs Prognostic biomarkers provide information about overall outcome Predictive biomarkers give information about the effects of treatment 11 Tejpar S, et al. Oncologist. 2010;15:390-404.
Slide 12-

Biomarkers in CRC: Current Status Several candidate biomarkers have been identified: KRAS mutation BRAF mutation Shortened survival or no value Negative outcome with anti-EGFR agents in mCRC Prognostic Predictive Poor prognosis Negative outcome with anti-EGFR agents in mCRC Prognostic Predictive 12 Tejpar S, et al. Oncologist. 2010;15:390-404.
Slide 13-

KRAS Mutations in CRC Present in 35-45% of CRC1 May be associated with shortened survival1 Predictive marker of response to EGFR therapy in CRC:1 Only patients with wild-type KRAS benefit from cetuximab/panitumumab Patients should be screened for KRAS status at the time of diagnosis of stage IV disease, prior to treatment2 13 Tejpar S, et al. Oncologist. 201;15:390-404. NCCN Colon Cancer: Version 1, 2013.
Slide 14-

ppt slide no 14 content not found
Slide 15-

Page 15
Slide 16-

Page 16
Slide 17-

Page 17
Slide 18-

Page 18
Slide 19-

Page 19
Slide 20-

Page 20
Slide 21-

Page 21
Slide 22-

Page 22
Slide 23-

Page 23
Slide 24-

ppt slide no 24 content not found
Slide 25-

ppt slide no 25 content not found
Slide 26-

ppt slide no 26 content not found
Slide 27-

ppt slide no 27 content not found
Slide 28-

ppt slide no 28 content not found
Slide 29-

ppt slide no 29 content not found
Slide 30-

ppt slide no 30 content not found
Slide 31-

ppt slide no 31 content not found
Slide 32-

ppt slide no 32 content not found
Slide 33-

ppt slide no 33 content not found
Slide 34-

ppt slide no 34 content not found
Slide 35-

ppt slide no 35 content not found
Slide 36-

ppt slide no 36 content not found
Slide 37-

ppt slide no 37 content not found
Slide 38-

ppt slide no 38 content not found
Slide 39-

ppt slide no 39 content not found
Slide 40-

ppt slide no 40 content not found
Slide 41-

ppt slide no 41 content not found
Slide 42-

ppt slide no 42 content not found
Slide 43-

ppt slide no 43 content not found
Slide 44-

ppt slide no 44 content not found
Slide 45-

ppt slide no 45 content not found
Slide 46-

ppt slide no 46 content not found
Slide 47-

ppt slide no 47 content not found
Slide 48-

ppt slide no 48 content not found
Slide 49-

ppt slide no 49 content not found
Slide 50-

ppt slide no 50 content not found
Slide 51-

ppt slide no 51 content not found
Slide 52-

ppt slide no 52 content not found
Slide 53-

ppt slide no 53 content not found
Slide 54-

ppt slide no 54 content not found
Slide 55-

ppt slide no 55 content not found
Slide 56-

56
Slide 57-

57
Slide 58-

58
Slide 59-

59
Slide 60-

60
Slide 61-

61
Slide 62-

62
Slide 63-

63
Slide 64-

64
Slide 65-

65
Slide 66-

66
Slide 67-

67
Slide 68-

68
Slide 69-

69
Slide 70-

70
Slide 71-

ppt slide no 71 content not found
Slide 72-

72
Slide 73-

73
Slide 74-

74
Slide 75-

75
Slide 76-

76
Slide 77-

77
Slide 78-

78
Slide 79-

79
Slide 80-

80
Slide 81-

81
Slide 82-

82
Slide 83-

83
Slide 84-

84
Slide 85-

85
Slide 86-

86
Slide 87-

87
Slide 88-

88
Slide 89-

89
Slide 90-

90
Slide 91-

91
Slide 92-

92
Slide 93-

93
Slide 94-

94
Slide 95-

95
Slide 96-

96
Slide 97-

97
Slide 98-

98
Slide 99-

99
Slide 100-

100
Slide 101-

101
Slide 102-

102
Slide 103-

103
Slide 104-

104
Slide 105-

105
Slide 106-

106
Slide 107-

107
Slide 108-

108
Slide 109-

109
Slide 110-

Thank you!